Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate

References

• Antithrombotic Trialist’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Goldwin J, Peto R, Buring J, Hennekens G, Kearney P, Meade T, et al. Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate. Lancet 2009;373:1849–1860
   Google Scholar
• Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med 2008; 121: 43–49
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606–617
   PubMed Web of Science ®Google Scholar
• Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increase platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45–49
   PubMed Web of Science ®Google Scholar
• Macchi L, Petit E, Brizard A, Gil R, Neau JP. Aspirin resistance in vitro and hypertension in stroke patients. J Thromb Haemost 2004; 2: 2051–2053
   PubMed Web of Science ®Google Scholar
• Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, III, TOAST. Investigator. Classification of subtypes of acute ischaemic stroke. Definition for use in a multicenter clinical trial. Stroke 1993; 24: 35–41
   PubMed Web of Science ®Google Scholar
• Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778–1781
   PubMed Web of Science ®Google Scholar
• Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997; 89: 1939–1943
   PubMed Web of Science ®Google Scholar
• Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, Daly ME. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation 2001; 104: 1459–1463
   PubMed Web of Science ®Google Scholar
• Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989–995
   PubMed Web of Science ®Google Scholar
• Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acid Res 2001; 29: E88–8
   PubMed Web of Science ®Google Scholar
• Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002; 48: 983–988
   PubMed Web of Science ®Google Scholar
• Hovens MCM, Snoep JD, Eikenboom JCJ, Van der Bom JG, Mertens BJA, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am Heart J 2007; 153: 175–181
   PubMed Web of Science ®Google Scholar
• Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001–1005
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175–178
   PubMed Web of Science ®Google Scholar
• Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006; 1: 31–35
   Google Scholar
• Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345–350
   PubMed Web of Science ®Google Scholar
• Blann AD, Lanza F, Galajda P, Gurney D, Moog S, Cazenave JP, Lip GYH. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis. The influence of aspirin and cigarette smoking. Thromb Haemost 2001; 86: 777–783
   PubMed Web of Science ®Google Scholar
• Linden MD, Furman MI, Frelinger AL, III, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelets activation and the stability of coronary artery disease. J Thromb Haemost 2007; 5: 761–765
   PubMed Web of Science ®Google Scholar
• Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100TM closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444–450
   PubMed Web of Science ®Google Scholar
• Lominadze D, Schuschke DA, Joshua IG, Dean WL. Increased ability of erythrocytes to aggregate in spontaneously hypertensive rats. Clin Exp Hypertens 2002; 24: 397–406
   PubMed Web of Science ®Google Scholar
• Kearnet-Schwartz A, Virion JM, Stoltz JF, Drouin P, Zannad F. Haemorheological disturbances in hypertensive type 2 patients: Influence of hypertensive therapy. Fundam Clin Pharmacol 2007; 21: 387–396
   PubMed Web of Science ®Google Scholar
• Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M, Broekman MJ, Marcus AJ. Platelet-erythrocyte interactions enhance aIIab3 integrin receptor activation and P-selectin expression during platelet recruitment: Down regulation by aspirin ex vivo. Blood 2002; 99: 3978–3984
   PubMed Web of Science ®Google Scholar
• Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 1991; 87: 571–580
   PubMed Web of Science ®Google Scholar
• Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity: Reduction by aspirin. Circulation 1997; 95: 63–68
   PubMed Web of Science ®Google Scholar
• Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ. Erythrocytes promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350–355
   PubMed Web of Science ®Google Scholar
• Santos MT, Valles J, Aznar J, Lago A, Sanchez E, Cosin J, Moscardo A, Pinon M, Broekman MJ, Marcus AJ. Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease. J Lab Clin Med 2006; 147: 220–227
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, et al. Lack of association between P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116: 491–497
   PubMed Web of Science ®Google Scholar
• Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A. Resistance in vitro to low dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia-IIa) and C-5T Kozak (GP Ibα) polymorphisms. J Am Coll Cardiol 2003; 42: 1115–1119
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am J Cardiol 2005; 149: 675–680
   Google Scholar
• Lepäntalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, Karhunen PJ, Lassila R. Polymorphism of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253–259
   PubMed Web of Science ®Google Scholar
• Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006; 27: 2165–2169
   PubMed Web of Science ®Google Scholar
• Ollikainen E, Mikkelsson J, Perola M, Penttilä A, Karkhunen PJ. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infraction in middle-aged men. Atherosclerosis 2004; 176: 95–99
   PubMed Web of Science ®Google Scholar
• Heemskerk JW, Siljander P, Vuist WM, Breikers G, Reutelingsperger CPM, Barnes MJ, Knight CG, Lassila R, Farndale RW. Function of glycoprotein VI and integrin a2b1 in the procoagulant response of single, collagen adherent platelet. Thromb Haemost 1999; 81: 782–792
   PubMed Web of Science ®Google Scholar